Skip to main content
Sign In

DEPARTMENT OF IMMUNOLOGY & MICROBIOLOGY, A Leader in Immunology, Microbiology and Microbial Pathogenesis Research and Training

Immunology and Microbiology

Donald Bellgrau, Ph.D.

Professor of Immunology & Microbiology

12800 E. 19th Ave., RC1-N 8113
Mail Stop 8333, Aurora, CO 80045

Phone: TBD

My primary research interest is translational research as it relates to immunotherapy. These interests have been influenced greatly by my involvement at the Barbara Davis Center for Childhood Diabetes where as a member of the research staff  I experienced first hand the devastating consequences of disease on both the patient and the family and at the University  of Colorado Cancer Center where, as Program Leader in Immunology/Immunotherapy, I immersed myself in the  immunobiology of cancer therapy and had the opportunity to take my research interests in this area to the clinic via my participation as a founding scientist of GlobeImmune Inc..  GlobeImmune has presently completed both Phase I and Phase II testing in humans for an immunotherapy technology invented by my collaborators and me that targets cancer and infections disease


1974-1978 ​University of Pennsylvania Teaching Fellowship, Department of Biology
1975-1978 ​University of Pennsylvania, Immunology Graduate Group Pre-doctoral Trainee Fellowship CA-09140 Mentor:  Darcy B. Wilson
1978-1979 ​Fellow of the American Cancer Society, Uppsala University, Sweden
1979-1980 Damon Runyon Fellow, Uppsala University, Sweden.  Mentor H. Wigzell
1980-1983 Member Research Staff, Basel Inst. For Immunology, Basel Switzerland
1983-1988 ​Assistant Professor, Department of Micro/Immunology, University of CO
1983-2002 ​Investigator, Barbara Davis Center for Childhood Diabetes
​1988-1998 ​Associate Professor with Tenure, Department of Immunology, U. of CO SOM
2003-2011 ​Program Leader, Immunology/Immunotherapy, Univer. of CO Cancer Center
1998-present Professor Department of Immuno/Micro, University of Colorado SOM
​2000 ​Founding scientist GlobeImmune, Inc. A publically traded company
​2005 ​Colorado Life Sciences Inventor of the Year        
​2006 ​Pinnacle Award to faculty entrepreneurs who show a strong commitment to    best practices in technology transfer
​2010 ​The Colorado Technology Transfer Award as Company of the Year

​“Use of Fas Ligand to Suppress T lymphocyte Mediated Immune Responses” ​#5,759,536 Issued 05/02/98
​“Yeast-Dendritic Cell Vaccines and Uses Thereof” ​#7,083,787 Issued 08/01/06
​“Yeast Based Delivery Vehicles” ​#7,465,454 Issued 12/16/08
​“Yeast-Based Vaccines as Immunotherapy” ​#7,563,447 Issued 07/21/09
#8,067,559 Issued 11/29/11
#8,153,136 Issued 04/10/12
#8,337,830 Issued 12/25/12
#8,343,502 Issued 01/01/13
#8,734,778 Issued 05/27/14
​“Yeast-Antigen Compositions. Methods of Making the Same” ​#7,595,060 Issued 09/29/09
​“Ras mutation and compositions and methods related thereto” ​#7,745,128 Issued 06/29/10
#8,470,313 Issued 05/23/13
​“Yeast-antigen compositions and methods of using the same” ​#8,221,763 Issued 07/17/12
​“Viral Vectors Encoding Apoptosis-Inducing Proteins and Methods for Making and Using the Same” ​#8,715,645 Issued 05/06/14
Recent Peer-reviewed Publications (from >100 peer-reviewed publications, 78 listed in pubmed)

Tamburini, B.A., Kedl, R.M. and Bellgrau, D. 2012 IL-6 inducing, whole yeast-based immunotherapy directly controls IL-12 dependent CD8 T cell responses.  J. of Immunotherapy 35:14-22

Bellgrau, D., Modiano, J.F. Cutter G.R, Lana, S.E, Ehrhart, N.P., Ehrhart, E.J. , Wilke, V.L., Charles, J.B., Munson, S., Scott, M.C., Pozniak, J., Schaack, J. and Duke, R.C. 2012  Inflammation, apoptosis, and necrosis induced by neoadjuvant Fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Molecular Therapy 12:2234-43

May, S.L.,, Zhou, Q., Lewellen, M., Carter, C.M., Coffey, D., Highfill, S.L.. Bucher, C.M., Matise, I., Morse, H., O’Sullivan, M.G., Schutten|, M.,  Bellgrau, D., Blazar, B.R., Modiano, J.F.  2014  Intrinsic negative regulators of effector T cell proliferation NFATc2 and Tob-1 have distinct roles in regulatory T cell function. PLOS ONE accepted for publication

King, T.H., Kemmler, C.B., Gu0, Z., Mann, D., Lu, Y., Coeshott, C., Gehring, A.D., Bertoletti, A., Ho, Z.Z., Delaney, W., Gaggar, A., Subramanian, M., McHutchison, J.G., Shrivastava, S., Lee, Y.L., Kottilil, S.,
Bellgrau, D., Rodell, T. and Apelian. D. 2014  A whole recombinant yeast-based theraeutic vaccine elicits HBV X, S and core specific T cells in mice and activates human specific  T cells recognizing epitopes linked to viral clearance. PLOS ONE accepted for publication

Click here for a list of Dr. Bellgrau's recent publications.